ERBB2 and breast carcinoma: Additionally, a comprehensive analysis of several large clinical studies demonstrated that HER2-low status is associated with increased resistance to NACT in HR-positive breast cancer patients (13.7% of HER2-low patients vs. 19.8% of HER2-negative patients, P = 0.014)11.